AstraZeneca Pharma India · NSE: ASTRAZEN · BSE: 506820
Q1 FY22 results · Apr–Jun 2021
AstraZeneca Pharma India reported revenue from operations of ₹175.40 crore (down 90.9% from Q1 FY21) and net profit of ₹10.24 crore (down 94.5% from Q1 FY21) for Q1 FY22 (Apr–Jun 2021), on a standalone basis.
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 175.40 | 1,935.78 | −90.9% | 210.26 | −16.6% |
| Other income | 2.90 | 26.48 | −89.0% | 2.55 | +13.6% |
| Total income | 178.30 | 1,962.26 | −90.9% | 212.81 | −16.2% |
| Profit before tax | 13.50 | 263.84 | −94.9% | 36.84 | −63.3% |
| Net profit for the period | 10.24 | 186.35 | −94.5% | 27.28 | −62.4% |
| EPS, basic (₹) | 4.10 | 7.45 | not comparable | 10.91 | −62.5% |
| Net margin (%) | 5.8 | 9.6 | 13.0 |
Standalone
- Filed with BSE
- 10 Aug 2021, 12:23 IST
- Board meeting
- 09 Aug 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE